In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations. Transaminase elevation rates (6.5%) and clinical hepatic event rates (5.9 events/100 person exposure years) were lower in the tipranavir/ritonavir with enfuvirtide group than in the tipranavir/ritonavir without enfuvirtide group. Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity.

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST / F. Raffi, M. Battegay, S. Rusconi, M. Opravil, G. Blick, R. T. Steigbigel, M. Kraft, D. Neubacher, J. P. Sabo. - In: AIDS. - ISSN 0269-9370. - 21:14(2007 Sep 12), pp. 1977-80-1980. [10.1097/QAD.0b013e3282ef8600]

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST

S. Rusconi;
2007

Abstract

In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations. Transaminase elevation rates (6.5%) and clinical hepatic event rates (5.9 events/100 person exposure years) were lower in the tipranavir/ritonavir with enfuvirtide group than in the tipranavir/ritonavir without enfuvirtide group. Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity.
Randomized Controlled Trials as Topic; HIV Protease Inhibitors; Liver Diseases; Pyrones; Anti-HIV Agents; Saquinavir; Humans; Pyridines; HIV-1; Alanine Transaminase; Viral Load; Drug Therapy, Combination; HIV Envelope Protein gp41; Drug-Induced Liver Injury; Peptide Fragments; Lopinavir; Ritonavir; HIV Infections; Pyrimidinones; Treatment Outcome; HIV Fusion Inhibitors
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
resist 00002030-200709120-00021 AIDS 2007.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 357.43 kB
Formato Adobe PDF
357.43 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/186793
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 15
social impact